Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
4
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
4
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
boston top stories
deals
gilead sciences
indiana blog main
indiana top stories
novartis
startups
alzheimer's disease
amgen
astrazeneca
biogen
cancer
cancer immunotherapy
covid-19
crispr
What
bio
ceo
4
×
roundup
4
×
acquisitions
biggest
crispr
daniel
drug
gilead
moves
o’day
sciences
week
albert
announced
big
bosley's
bosley’s
bourla
bridge
bucks
build
buy
cas
collabs
company
company’s
covid
crime
deal
debut
departure
dyne’s
editas
exit
future
gilead’s
guiding
help
imports
Language
unset
unknown
Current search:
roundup
×
" raleigh-durham blog main "
×
" san francisco top stories "
×
ceo
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More